Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-05-02 | Spago Nanomedical | Spago Nanomedical interim report January-March 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-02 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical reports favorable data in breast cancer model with Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical rapporterar gynnsamma data i bröstcancermodell med Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical strengthens management with Head of CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical stärker ledningen med chef för CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 28 mar 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-03-27 | Spago | BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding" | Pressreleaser | Visa Stäng |
|
||||
2024-02-09 | Spago | BioStock: 2023 springboard for Spago's radionuclide cancer therapy | Pressreleaser | Visa Stäng |
|
||||
2024-02-08 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Lockande nyhetsagenda | Pressreleaser | Visa Stäng |
|
||||
2024-02-08 | Redeye | Redeye: Spago Nanomedical Q4 Update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical year-end report January-December, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical bokslutskommuniké januari-december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-25 | Spago Nanomedical | The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-25 | Spago Nanomedical | Företrädesemissionen och den riktade emissionen till vissa garanter i Spago Nanomedical slutregistrerade | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presenterar på Redeyes temadag Fight Cancer den 24 januari | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-15 | Spago | BioStock: Spago's phase I/IIa cancer trial progressing steadily | Pressreleaser | Visa Stäng |
|
||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical går vidare till nästa dosnivå i fas I/IIa-studien Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-03 | Redeye | Redeye: Spago Nanomedical - Update after funding and initiation of Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Spago | BioStock: Positive data in Spago's phase IIa endometriosis trial | Pressreleaser | Visa Stäng |
|
||||
2023-12-18 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Uppmuntrande resultat | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-14 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 14 dec 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Spago | BioStock: First patient dosed in Spago's phase I/IIa trial | Pressreleaser | Visa Stäng |
|
||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical carries out a directed issue of shares to guarantors following the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical genomför riktad nyemission av aktier till garanter efter den genomförda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-12 | Spago Nanomedical | Rights issue in Spago Nanomedical partially registered | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-12 | Spago Nanomedical | Företrädesemissionen i Spago Nanomedical delregistrerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Spago Nanomedical | Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Spago Nanomedical | First patient dosed in Spago Nanomedical's clinical phase I/IIa study within the Tumorad® program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical announces outcome of the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Spago Nanomedical | Last day of the subscription period in Spago Nanomedical’s rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Spago Nanomedical | Sista dagen i teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Spago Nanomedical | Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Spago Nanomedical | Valberedning utsedd inför Spago Nanomedicals årsstämma 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Spago Nanomedical | Idag börjar teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Spago Nanomedical | The subscription period in Spago Nanomedical’s rights issue begins today | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Penser Access | Penser Access: Betydelsefullt stöd från huvudägare - Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical offentliggör prospekt med anledning av förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical publishes prospectus in connection with forthcoming rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical interim report January-September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Spago Nanomedical | Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Spago Nanomedical | Kommuniké från extra bolagsstämma i Spago Nanomedical AB den 31 oktober 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng |
|
||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng |
|
||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical ansöker om utökat patentskydd för Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical applies for extended patent protection for Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-23 | Spago | BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa | Pressreleaser | Visa Stäng |
|
||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Spago | Spago Nanomedical presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Penser Access | Penser Access: Intervju med Spago Nanomedical - Erik Penser Bank - 11 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-14 | Penser Access | Penser Access: Sticker ut i mängden - Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-08-01 | Redeye | Redeye: Spago Nanomedical Q2 - Milestone almost concluded, continued cost control crucial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical interim report January-June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Spago | BioStock: Spago Nanomedical's SAB on Tumorad's potential | Pressreleaser | Visa Stäng |
|
||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Spago | BioStock: Spago Nanomedical's CDO on study submission | Pressreleaser | Visa Stäng |
|
||||
2023-05-30 | Spago | BioStock: Spago Nanomedicals CDO om studieansökan | Pressreleaser | Visa Stäng |
|
||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Spago | BioStock: Tumorad clinical start around the corner for Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | Redeye | Redeye: Spago Nanomedical - Pivotal year ahead | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Spago Nanomedical | Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Bulletin from the 2023 Annual General Meeting of Spago Nanomedical ABThe Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 10, 2023. At the AGM, changes were resolved in the company’s board for increased commercial focus, including the election of Hans Arwidsson as new chairman of the board and Alan Raffensperger as a new board member. The following resolutions were also passed at the AGM: Disposition of results and discharge from liability The income statement and balance sheet for 2022 were approved and the board members and the CEO were discharged from liability for the financial year 2022. Election of board and board fees Board fees for the period until the end of the next AGM shall be SEK 300,000 (SEK 200,000) to the chairman of the board and SEK 150,000 (SEK 95,000) to each of the other board members. Election of auditor and auditor fee Authorisation for the Board to resolve to issue new shares and/or warrants Resolution on amendment of the Articles of Association and reduction of the share capital |
||||
2023-05-10 | Spago Nanomedical | Kommuniké från årsstämma 2023 i Spago Nanomedical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Spago Nanomedical | Spago Nanomedical interim report January-March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Spago Nanomedical | Presentation of Spago Nanomedical's clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Spago Nanomedical | Presentation av Spago Nanomedicals kliniska fas IIa-studie i endometrios vid 15th World Congress of Endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|